Executive Summary
GLP-1 and metabolic therapeutics are now the central axis of the pharmaceutical industry’s obesity and diabetes franchises. The core technology is not a single molecule but a family of peptide and small-molecule agonists that activate the glucagon-like peptide-1 receptor, and in some newer compounds co-activate or co-modulate the glucose-dependent insulinotropic polypeptide receptor and glucagon receptor. The evidence base shifted from glucose control into hard cardiovascular and weight-loss outcomes, and the commercial battlefield is now patent protection, reimbursement, compounding, and manufacturing capacity.
The strongest peer-reviewed evidence for efficacy comes from the STEP and SURMOUNT trial programs, led by semaglutide and tirzepatide. Those trials are not marketing summaries; they are randomized, placebo-controlled, peer-reviewed publications with verifiable DOI identifiers. The strongest patent evidence for early GLP-1/exendin technology is a granted U.S. patent, U.S. Patent No. 5,424,286, and the strongest regulatory evidence is FDA approval of semaglutide 2.4 mg for chronic weight management.
This note distinguishes granted patents from applications and peer-reviewed papers from preprints. It treats patents as recorded claims, not proof of commercial performance — a point that matters heavily in this sector because compound patents, formulation patents, and method-of-use patents are being litigated and challenged.
Mechanism and Product Architecture
2.1 Endogenous GLP-1 and the Problem It Solves
Glucagon-like peptide-1 is an incretin hormone secreted after nutrient intake. It potentiates glucose-stimulated insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces food intake through central nervous system pathways. The central problem for drug development is that native GLP-1 is rapidly degraded by dipeptidyl peptidase-4, so its native half-life is measured in minutes. Therapeutics therefore need structural changes that resist DPP-4 cleavage, prolong half-life, or both.
The granted patent for early exendin-based GLP-1 technology is:
- U.S. Patent No. 5,424,286 — granted 1995-06-13 — covers exendin-3, exendin-4, and related peptide derivatives. This is the foundational exendin patent behind exenatide and the broader peptide class. It is a granted patent, not an application.
Source: [patents.google.com — accessed 2026-05-09.
2.2 Product Architectures: Peptide Backbones, Acylation, and Dual/Triple Agonism
The modern products are not identical molecules. Semaglutide is a GLP-1 receptor agonist with a long fatty-acid side chain that binds albumin, extending half-life to about one week for subcutaneous dosing. Tirzepatide is a dual GIP/GLP-1 receptor agonist, also with an extended half-life. Oral semaglutide uses an absorption enhancer, SNAC, to permit gastric absorption of a peptide that would otherwise be degraded.
The performance claims rest on randomized trial data, not on the patent claims:
- Semaglutide 2.4 mg subcutaneous, STEP 1 trial: mean body-weight change was –14.9% in the semaglutide group versus –2.4% in the placebo group, at week 68. This is a placebo-subtracted reduction of approximately 12.5 percentage points. The trial enrolled adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity.
Source: Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183 — published 2021-03-18 — accessed 2026-05-09.
- Tirzepatide 15 mg, SURMOUNT-1 trial: mean body-weight change at week 72 was –20.9% for 15 mg, –19.5% for 10 mg, and –15.0% for 5 mg, versus –3.1% for placebo.
Source: Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine 2022;387:205–216. DOI: 10.1056/NEJMoa2206038 — published 2022-07-21 — accessed 2026-05-09.
2.3 What a Patent Does and Does Not Prove
The patent record is important for moat analysis, but it is evidence of claimed subject matter, not evidence of safety or efficacy. The efficacy evidence above comes from peer-reviewed trials; the patent gives legal blocking power only if the granted claims are valid, enforceable, and actually cover a commercial product. In this class, patent disputes are common. A granted patent may be invalidated or narrowed in inter partes review or district-court litigation. Therefore, a patent strengthens a moat only when paired with product-level clinical and regulatory evidence.
This note uses only the granted patent U.S. Patent No. 5,424,286 for the foundational exendin claim. Additional Orange Book patents covering semaglutide and tirzepatide formulations and methods of use exist, but specific granted numbers and current validity disputes require primary-source validation against the FDA Orange Book and court dockets; they are not used here as load-bearing moat claims.
Clinical Evidence Base and Cross-Validation
3.1 Tier 1 Peer-Reviewed Performance Data
The strongest efficacy claims are cross-verified by multiple independent institutions. The STEP 1 publication lists academic investigators from multiple institutions; the SURMOUNT-1 publication similarly includes a multi-institution author group. These are not company-only papers. The FDA approval records independently reviewed the same trial data.
For semaglutide 2.4 mg, two independent source lineages support the performance claim:
- Peer-reviewed trial: Wilding et al. 2021, DOI 10.1056/NEJMoa2032183.
- Regulator approval: FDA approved semaglutide 2.4 mg injection (Wegovy) for chronic weight management on 2021-06-04. Source: FDA press announcement, [fda.gov — accessed 2026-05-09.
That is two independent institutions: the NEJM peer-review process and the FDA.
For tirzepatide, the performance claim is cross-verified by the SURMOUNT-1 publication and FDA approval of tirzepatide for chronic weight management on 2023-11-08. Source: FDA press announcement, [fda.gov — accessed 2026-05-09.
3.2 Categorical Response and Effect Size
The continuous mean weight-loss number can hide responders and non-responders. STEP 1 reported categorical outcomes: approximately 86.4% of semaglutide 2.4 mg participants achieved ≥5% weight loss, versus 31.5% of placebo participants. These categorical numbers permit a number-needed-to-treat calculation.
Calculation 1: Number needed to treat for ≥5% weight loss
Formula:
\[
NNT = \frac{1}{\text{proportion achieving} \ge 5\% \text{ in drug} - \text{proportion achieving} \ge 5\% \text{ in placebo}}
\]
Inputs:
- Semaglutide proportion with ≥5% weight loss: 0.864
- Placebo proportion with ≥5% weight loss: 0.315
\[
NNT = \frac{1}{0.864 - 0.315} = \frac{1}{0.549} \approx 1.82
\]
Interpretation: roughly every 2 patients treated with semaglutide 2.4 mg in a trial setting, one additional patient achieves ≥5% weight loss attributable to semaglutide, beyond placebo.
Sensitivity analysis:
- If drug response were 0.80 and placebo 0.35, NNT = 1 / 0.45 ≈ 2.22.
- If drug response were 0.90 and placebo 0.30, NNT = 1 / 0.60 ≈ 1.67.
- If placebo response were 0.40 and drug response 0.864, NNT = 1 / 0.464 ≈ 2.16.
The NNT is sensitive mainly to the placebo response rate, which varies by trial intensity and population. The conclusion that semaglutide has a large categorical effect is robust across these sensitivity ranges.
Source for the categorical inputs: Wilding et al. 2021, DOI 10.1056/NEJMoa2032183 — accessed 2026-05-09.
3.3 Body Weight: Absolute Effect and Energy Deficit Derivation
The mean absolute body-weight loss in STEP 1 is clinically meaningful but depends on baseline weight. The semaglutide-group baseline mean body weight was approximately 105.4 kg.
Calculation 2: Absolute weight loss and implied daily energy deficit
Formula:
\[
\Delta \text{weight}_{kg} = \text{baseline}_{kg} \times \frac{\Delta\%_{drug} - \Delta\%_{placebo}}{100}
\]
Inputs:
- Baseline body weight: 105.4 kg
- Drug weight change: –14.9%
- Placebo weight change: –2.4%
\[
\Delta \text{weight}_{kg} = 105.4 \times \frac{-14.9 - (-2.4)}{100} = 105.4 \times (-0.125) = -13.175 \text{ kg}
\]
So the placebo-adjusted absolute loss is about 13.2 kg for a 105.4 kg patient.
Sensitivity:
- 80 kg baseline: \(80 \times 0.125 = 10.0\) kg net loss.
- 120 kg baseline: \(120 \times 0.125 = 15.0\) kg net loss.
- If placebo response were higher, say –3.5%, the difference falls to 11.4 percentage points; absolute loss for 105.4 kg becomes 12.0 kg.
Energy deficit derivation:
Using a standard fat-energy density of approximately 7,700 kcal/kg body fat, the total energy represented by 13.175 kg of fat is:
\[
13.175 \text{ kg} \times 7,700 \text{ kcal/kg} = 101,447.5 \text{ kcal}
\]
Over the 68-week trial period:
\[
68 \text{ weeks} \times 7 = 476 \text{ days}
\]
\[
\text{Daily implied energy deficit} = \frac{101,447.5}{476} \approx 213 \text{ kcal/day}
\]
This is a derived estimate, not a direct measurement of food intake or energy expenditure. It assumes all weight change is fat mass and uses a fixed energy density. The calculation is useful for illustrating the modest long-term daily energy gap that can produce large cumulative weight changes.
Source for energy-balance framework: Hall KD, et al. “Quantification of the effect of energy imbalance on bodyweight.” The Lancet 2011;378:826–837. DOI: 10.1016/S0140-6736(11)60812-X — published 2011-08-27 — accessed 2026-05-09. The 7,700 kcal/kg figure is a standard dietetic conversion; product-specific energy expenditure was not measured in STEP 1.
Patent Landscape and Moat Analysis
4.1 Granted Patent vs. Patent Application
For moat analysis, only granted patents count as enforceable rights. U.S. Patent No. 5,424,286 is a granted patent, issued 1995-06-13. It covers the early exendin peptide work. It is not an application and is not a preprint.
In contrast, patent applications in this field are plentiful. This note does not use any application number to support a moat claim. An application is only a disclosure and a pending claim; it has not been examined and granted.
4.2 What the Granted Patent Does and Does Not Cover
U.S. Patent No. 5,424,286 is tied to exendin-3 and exendin-4 peptides and derivatives. It is historically important because exenatide, the first marketed GLP-1 receptor agonist approved for Type 2 diabetes, descended from exendin-4. The patent is not a statement that exenatide or semaglutide is effective; it merely records claimed peptide sequences and uses.
The commercial moat today is not primarily this 1995 patent. Modern semaglutide and tirzepatide products are covered by later patents, regulatory exclusivities, and supply-chain complexity. Those later patents must be verified individually against the FDA Orange Book. This note therefore does not assert a specific Orange Book patent number for semaglutide or tirzepatide. Any load-bearing claim about current exclusivity expiration dates would need an Orange Book citation; without that, it is needs primary source validation.
4.3 Why Patents Are Contested Here
The market size and pricing create intense litigation. Patent invalidation or non-infringement findings would open the field to earlier generic or biosimilar entry. This is a risk factor disclosed in company filings. Patent protection is therefore best modeled as a contested asset, not a guaranteed moat.
Regulatory Status and Company Filings
5.1 FDA Approvals
Two regulatory decisions anchor the current market:
- Semaglutide 2.4 mg (Wegovy) approved 2021-06-04 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Source: FDA, [fda.gov — accessed 2026-05-09.
- Tirzepatide (Zepbound) approved 2023-11-08 for chronic weight management.
Source: FDA, [fda.gov — accessed 2026-05-09.
5.2 SEC Filing Risk Factors
Company filings are a separate source tier and are appropriate for adoption, reimbursement, and competitive context, but they are self-reported. Key risk-factor themes from GLP-1 manufacturers include:
- Pricing and reimbursement pressure: U.S. payers and pharmacy benefit managers increasingly impose utilization management, prior authorization, and formulary exclusions. This is disclosed in annual filings.
- Manufacturing capacity constraints: Injectable pen capacity, fill-finish, and device components are bottlenecks.
- Competition: Novo Nordisk’s and Eli Lilly’s filings both identify the other’s incretin products, plus oral small-molecule candidates, as material competitive threats.
- Clinical and regulatory risk: Cardiovascular outcomes trials, pediatric indications, and renal outcomes remain ongoing or subject to regulatory review.
Representative SEC filing sources:
- Eli Lilly 10-K filings index: [sec.gov — accessed 2026-05-09.
- Novo Nordisk 20-F filings index: [sec.gov — accessed 2026-05-09.
These are SEC index URLs; the specific accession numbers for the latest annual reports require opening the latest filing from the index.
5.3 Marketing vs. Filing Disclosures
Investor materials and product websites emphasize the average weight-loss percentages from the trials. SEC filings emphasize risks: insurance coverage may not match trial populations; real-world persistence may be lower; supply may be constrained; competitors may launch oral agents. The discrepancy is not illegal, but it is a standard promotional-versus-risk-disclosure gap. Investors should read the risk factors, not only the investor presentations.
Specific revenue or margin figures for GLP-1 products are not used in this note because product-level margins are not consistently disclosed in public filings. Company-level financials are disclosed but would require specific line-item retrieval from the applicable annual report; any figure quoted from memory is needs primary source validation.
Unit Economics / Business Model
6.1 Who Monetizes
The primary monetizers are branded pharmaceutical manufacturers:
- Novo Nordisk monetizes semaglutide through Ozempic, Wegovy, and Rybelsus. The business model is direct prescription drug sales, with gross-to-net deductions from rebates and discounts to PBMs and payers.
- Eli Lilly monetizes tirzepatide through Mounjaro and Zepbound, and has oral candidates in development.
- Contract development and manufacturing organizations (CDMOs), including Catalent, monetize fill-finish and device assembly capacity.
- Compounding pharmacies and telehealth platforms monetize compounded semaglutide during FDA-declared shortages, but this is a regulatory and legal gray zone, not a patent-protected business.
6.2 How They Monetize
- Prescription drug sales: per-patient, per-month pricing, subject to payer rebates.
- Self-pay/cash-pay: compounded and direct-to-consumer models.
- Service/CDMO: capacity contracts for sterile fill-finish, pen assembly, and packaging.
6.3 Margins
Pharmaceutical gross margins are structurally high, but product-level GLP-1 margins are not separately disclosed in SEC filings. Any specific margin percentage would be needs primary source validation. The economic sustainability of the brand model depends on insurance coverage breadth; if coverage narrows, patient out-of-pocket costs rise and persistence falls.
6.4 Who Captures Value
- Brand manufacturers capture the largest share of value via pricing power while patents and regulatory exclusivity hold.
- PBMs and payers capture value through rebates, tier placement, and utilization management.
- CDMOs capture value through capacity scarcity.
- Telehealth/compounding platforms capture value during shortages, but that value is fragile and regulatory-dependent.
Parameter Table and Calculated Results
| Parameter | Value | Source (URL + ID + date) | Tier | Measured / Derived / Assumed / Inferred | Cross-verified |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg mean weight change, STEP 1 | –14.9% | Wilding et al. 2021, DOI 10.1056/NEJMoa2032183, 2021-03-18 | Tier 1 | Measured | Yes |
| Placebo mean weight change, STEP 1 | –2.4% | Same as above | Tier 1 | Measured | Yes |
| Semaglutide ≥5% responder proportion | 86.4% | Same as above | Tier 1 | Measured | Yes |
| Placebo ≥5% responder proportion | 31.5% | Same as above | Tier 1 | Measured | Yes |
| STEP 1 semaglutide group baseline body weight | 105.4 kg | Same as above | Tier 1 | Measured | Yes |
| Tirzepatide 15 mg mean weight change, SURMOUNT-1 | –20.9% | Jastreboff et al. 2022, DOI 10.1056/NEJMoa2206038, 2022-07-21 | Tier 1 | Measured | Yes |
| SURMOUNT-1 placebo mean weight change | –3.1% | Same as above | Tier 1 | Measured | Yes |
| Body fat energy density | 7,700 kcal/kg | Hall et al. 2011, DOI 10.1016/S0140-6736(11)60812-X, 2011-08-27 | Tier 1 | Derived / standard | Yes |
| Exendin patent grant date | 1995-06-13 | U.S. Patent No. 5,424,286, [patents.google.com | Tier 1 | Recorded | Yes |
| Wegovy FDA approval date | 2021-06-04 | FDA, [fda.gov | Tier 1 | Recorded | Yes |
| Zepbound FDA approval date | 2023-11-08 | FDA, [fda.gov | Tier 1 | Recorded | Yes |
Calculated outputs:
- NNT for one additional ≥5% weight-loss responder: 1.82 (sensitivity 1.67–2.22).
- Placebo-adjusted absolute weight loss for 105.4 kg patient: 13.2 kg (sensitivity 10.0–15.0 kg across baseline weight).
- Implied daily energy deficit from that weight loss: ≈213 kcal/day over 68 weeks. Derived, not directly measured.
Disconfirming Evidence
The thesis that GLP-1 and metabolic therapeutics are a durable, high-value technology would be materially weakened by any of the following:
- Negative or neutral cardiovascular outcomes: If long-term outcomes trials fail to show mortality or major adverse cardiovascular event benefit, the foundational medical rationale narrows.
- Severe safety signal: A reproducible signal of serious adverse events — for example, suicidal ideation, pancreatitis, or thyroid C-cell tumors — would reduce adoption and invite regulatory action.
- Loss of patent protection earlier than expected: If key Orange Book patents are invalidated or found not infringed, generic or biosimilar entry would compress branded pricing.
- Superior oral small molecules with better tolerability and efficacy: If a non-peptide oral candidate matches or exceeds tirzepatide with fewer gastrointestinal side effects, the injectable peptide moat weakens.
- Payer exclusion or step-edit restrictions: If employers and PBMs broadly exclude obesity indications or require prior authorization that suppresses persistence, real-world volumes would fall below trial-based projections.
- Compounding displacement: If compounded semaglutide becomes a permanent cash-pay alternative after shortages resolve, branded pricing power could erode.
Each of these is a testable condition. The current evidence supports strong clinical efficacy and a real commercial market, but the moat is not as simple as “patent plus trial result.” It depends on validity, enforcement, reimbursement, safety durability, and the next generation of oral and multi-agonist agents.